文献速递淋巴瘤

JULIET 试验中接受替沙来仑赛治疗患者细胞因子释放综合征的分级与管理

Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.
PubMed 文献 · Blood Adv · 2020-01-01

本研究回顾性重新分级 JULIET 试验(2 期、单臂、多中心)中 111 例复发/难治性弥漫大 B 细胞淋巴瘤患者接受替沙来仑赛后的细胞因子释放综合征(CRS)事件,比较 Penn、Lee 和 ASTCT 三种分级系统的一致性,并描述托珠单抗使用情况。结果显示 Lee 和 ASTCT 与 Penn 分级存在差异,且 111 例中 16 例(14%)因严重事件(Penn 3/4 级 CRS)接受托珠单抗。

要点

  • 111 例中 64 例按 Penn 分级有 CRS 事件,回顾性再分级后 Lee 和 ASTCT 分别有 63 和 61 例。
  • 与 Penn 相比,Lee 分级一致 39 例、降低 20 例、升高 5 例;ASTCT 一致 37 例、降低 23 例、升高 4 例。
  • 111 例中 16 例(14%)接受托珠单抗,全部用于严重事件(Penn 3/4 级 CRS)。

核心结论

  • 本研究首次使用同一患者数据集评估三种 CRS 分级系统的一致性,并比较 JULIET 试验与 ZUMA-1 试验中按 Lee 分级的托珠单抗使用情况。
  • 分析描述了分级系统之间的关键差异,可能为 CRS 管理实践提供参考。

研究设计与样本

  • JULIET 试验为 2 期、单臂、多中心试验(#NCT02445248),截至 2017 年 12 月 8 日共 111 例复发/难治性弥漫大 B 细胞淋巴瘤患者接受替沙来仑赛输注。
  • 四名具有三种不同 CAR-T 产品治疗经验的医学专家独立对患者个体层面的 CRS 事件进行回顾性重新分级。
  • 比较 Penn、Lee 和 ASTCT 三种分级系统之间的一致性。

主要发现

  • 111 例患者中,64 例按 Penn 分级有 CRS 事件;回顾性再分级后,按 Lee 和 ASTCT 标准分别有 63 例和 61 例有 CRS 事件。
  • 与 Penn 分级相比,Lee 分级一致 39 例、降低 20 例、升高 5 例;ASTCT 标准一致 37 例、降低 23 例、升高 4 例。
  • 111 例中 16 例(14%)接受托珠单抗,全部用于严重事件(Penn 3/4 级 CRS)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Cytokine release syndrome (CRS) is a CAR-T therapy-related adverse event. To date, clinical trials of different CAR-T products have not been aligned on CRS grading scales and management algorithms. We assessed concordance between the Penn, Lee, and American Society for Transplantation and Cellular Therapy (ASTCT) grading systems by retrospectively regrading CRS events in the JULIET (A Phase 2, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory DLBCL) trial. Four medical experts with experience treating patients with 3 different CAR-T products independently regraded individual patient-level CRS events from the phase 2, global, pivotal JULIET trial (#NCT02445248). As of 8 December 2017, a total of 111 patients with r/r DLBCL underwent infusion with tisagenlecleucel. Sixty-four patients had CRS events graded per the Penn scale; on retrospective review, 63 and 61 patients had CRS events regraded per the Lee and ASTCT criteria, respectively. The Lee scale yielded concordance for 39, lower grade for 20, and higher grade for 5 events compared with the Penn scale. The ASTCT criteria provided concordance for 37, lower grade for 23, and higher grade for 4 events compared with the Penn scale. Sixteen (14%) of 111 patients in the JULIET trial received tocilizumab, all for severe events (Penn grade 3/4 CRS). This study is the first to assess concordance between 3 CRS grading scales using the same patient data set and to compare tocilizumab use according to the Lee scale in the JULIET trial and the ZUMA-1 (Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma) trial. This analysis describes key differences between grading scales and may inform CRS management practices.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schuster SJ, Maziarz RT, Rusch ES, et al. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020. PMID: 32271899. doi:10.1182/bloodadvances.2019001304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。